Specialty CROs, WCCT Global and Medelis, Announce Merger to Deliver Expanded Oncology and Clinical Research Services
- Merger offers customers international reach combined with specialized oncology expertise for clinical trial development and implementation -
CYPRESS, Calif., June 1, 2016 /PRNewswire/ -- WCCT Global, an international specialized clinical research organization (CRO), and Medelis, Inc., a specialty oncology CRO, announced today that the companies have merged to offer US and international clients access to an expanded depth and breadth of clinical research offerings.
"The complex and rapidly growing oncology drug development market in the US, Europe, and Asia requires unique insight and expertise and an eye toward the future, all of which we now offer through this merger," said Dr. Kenneth Kim, founder and CEO of WCCT Global. "We're committed to delivering world-class clinical research solutions to achieve our vision of becoming the global leader in the development of specialized medicines and therapies."
Medelis will continue to provide the highest quality clinical research for all of Medelis' current and future studies. Bill Taaffe, the current president of Medelis and former president and CEO of ICON Clinical Research-US, will continue to lead Medelis.
"We now offer the solution for the many sponsors who have been asking for a single specialty oncology CRO to help them navigate all of the complexities of taking oncology and immuno-oncology drugs into the clinic in the US, Europe, and Asia," said Bill Taaffe, president of Medelis.
WCCT Global offers in-house project management, clinical monitoring, biostatistics and data management, an extensive investigator and patient recruitment network, clinical pharmacology units, and a translational medicine team for handling all aspects of regulatory affairs. The merger adds to these corporate offerings the extensive oncology expertise of Medelis and the experience of designing and managing preclinical and phase 1 through phase 4 studies at over 400 sites in North America and Europe.
"The addition of Medelis not only creates a more robust offering for our current and future clients, it also creates a stronger company with multiple synergies to fuel our future growth," stated Ron Linares, CFO of WCCT Global.
About WCCT Global
WCCT Global is a specialized CRO delivering early drug development and late phase CRO services to the pharmaceutical, biotechnology, and medical device industries. As a drug development partner, WCCT Global works with domestic and foreign companies to deliver regulatory guidance, program management, patient recruitment, data management, and strategic consulting, with an emphasis in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT is a leader in healthy volunteer studies, including first-in-human (FIH), as well as specific therapeutic expertise in allergy, asthma, HCV, ophthalmology, renal, and vaccines.
About Medelis, Inc.
Medelis is a specialty oncology CRO focused on preclinical and phase 1 through phase 4 oncology trials in North America and Europe. Founded in 2003, Medelis provides sponsors with oncology expertise from drug development thought-leadership to a highly skilled clinical operations team, handling complex oncology trials in all indications, including cutting-edge immunotherapy treatments.
SOURCE WCCT Global
Share this article